T-lymphocyte cytokine mRNA expression in cystic echinococcosis.
In the present study we investigated cytokine mRNA expression by peripheral blood mononuclear cells (PBMC) from patients with cystic echinococcosis (CE) after stimulation with different antigens. By using reverse transcriptase polymerase chain reaction (RT-PCR) we could demonstrate that restimulation with crude Echinococcus granulosus antigen (Eg-Ag) induced or enhanced Th2 cytokine mRNA expression, especially IL-5 (by using antigen from sheep cyst fluid) in 23 out of 26 investigated CE patients and IL-10 (by using antigen from camel cyst fluid) in 10 out of 10 investigated CE patients. In contrast, IL-5 mRNA expression was absent in PBMC of healthy controls after Eg-Ag stimulation. To determine the specificity of this reaction we stimulated PBMC from 11 CE patients with crude Echinococcus multilocularis antigen (Em-Ag) and PBMC from 8 CE patients with Toxocara canis antigen (Tc-Ag). We found that the PBMC of patients showed a similar mRNA cytokine pattern on stimulation with Em-Ag when compared with Eg-Ag stimulation. The cytokine mRNA pattern on stimulation with Tc-Ag, however, resembled the cytokine mRNA pattern of unstimulated PBMC. Furthermore, the stimulation of PBMC with crude Mycobacterium tuberculosis antigen (H37Ra) and purified protein derivative (PPD) of M. tuberculosis revealed distinct IL-5 mRNA expression in all investigated CE patients, whereas in healthy controls IL-5 mRNA expression was very weak or totally absent. Thus, our results indicate an induction of Th2 cytokine mRNA expression in CE patients, which is frequently observed in parasite infections. Interestingly, this response persists after stimulation with tuberculosis antigens, which normally induce Th1 response.
Fauser
S
S
Section of Infectious Diseases and Clinical Immunology, University Hospital and Medical Clinic, University of Ulm, Germany.
Kern
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000942:Antigens, Bacterial / Q000494:pharmacology; D000947:Antigens, Helminth / Q000494:pharmacology; D000980:Antiplatyhelmintic Agents / Q000627:therapeutic use; D003560:Cysts; D016207:Cytokines / Q000235:genetics*; D004443:Echinococcosis / Q000188:drug therapy / Q000276:immunology*; D004446:Echinococcus / Q000276:immunology*; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000276:immunology; D012333:RNA, Messenger / Q000097:blood*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D017166:Toxocara canis / Q000276:immunology; D014373:Tuberculin / Q000494:pharmacology
D000942:Antigens, Bacterial; D000947:Antigens, Helminth; D000980:Antiplatyhelmintic Agents; D016207:Cytokines; D012333:RNA, Messenger; D014373:Tuberculin